Amphotericin B lipid complex

Annals of Pharmacotherapy

Volumn 31, Issue 10, 1997, Pages 1174-1186

  Rapp, Robert P ^a,c   Gubbins, Paul O ^b   Evans, Martin E ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c University of Kentucky   (United States)

Author keywords

Amphotericin B lipid complex; Invasive mycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ANTIFUNGAL ACTIVITY; CHILL; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030922832     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101011     Document Type: Review

References (67)

1. Banerjee SN, Emori GT, Culver DH, Gaynes RP, Jarvis WR, Horan T, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91(suppl 3B):86S-9S.
2. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Arch Intern Med 1995;155:1177-84.
3. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
4. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Seth M, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-83.
5. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DH. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-62.
6. 31P-NMR study. Biochim Biophys Acta 1989;980:261-72.
7. Gruda I, Nadeau J, Brajtburg J, Medoff G. Application of different spectra in the UV-visible region to study the formation of amphotericin B complexes. Biochim Biophys Acta 1980;602:260-8.
8. Vertut-Croquin A, Bolard J, Chabert M, Gary-Bobo C. Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol-or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry 1983;22:2939-44.
9. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990;34;183-8.
10. Maddux MS, Barriere SL. A review of complications of amphotericin-B therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1980;14:177-81.
11. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980;302:145-55.
12. Bullock WE, Luke RG, Nuttall CE, Bhatahena D. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 1976;10: 555-63.
13. Symmers WSt.C. Amphotericin pharmacophobia. Br Med J 1973;4:460-3.
14. Ellis ME, Al-Hokail AA, Clink HM, Pamos MA, Ernst P, Spence DG, et al. Double blind randomized study of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992;36:172-9.
15. Oldfield EC, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990;34:1402-6.
16. Cruz JM, Peacock JE, Loomer L, Holder LW, Evans GW, Powell BL, et al. Rapid infusions of amphotericin B: a pilot study. Am J Med 1992;93: 123-30.
17. Branch RA. Prevention of amphotericin B induced renal impairment. Arch Intern Med 1988;148:2389-94.
18. Cruz J, Boardman L, Powell B, Peacock J, Freedman B, Hurd D, et al. Effects of amiloride on amphotericin B induced potassium wasting (abstract). In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 29-October 2, 1991:99.
19. Dennis VW, Stead NW, Andreoli TE. Molecular aspects of polyene-and sterol-dependent pore formation in thin lipid membranes. J Gen Physiol 1970;55:375-400.
20. Andreoli TE. The structure and function of amphotericin B-cholesterol pores in lipid bilayer membranes. Ann N Y Acad Sci 1974;235:448-68.
21. New RPC, Chance ML, Heath J. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981;8:371-81.
22. Graybill JR, Creven PC, Taylor RL, Williams DM, McGee WE. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982;145:748-52.
23. Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, McGee WE. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Ann Rev Resp Dis 1982;125:610-1.
24. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985;151:704-10.
25. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A 1988;85:6122-6.
26. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (Abelcet): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451-71.
27. Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Pasternack RF, et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107: 271-82.
28. Szoka FC, Tang M. Amphotericin B formulated in liposomes and lipid based systems: a review. J Liposome Res 1993;3:363-75.
29. Louie A, Baltcn AL, Franke MA, Smith RP, Gordon MA. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumor necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasome. J Antimicrob Chemother 1994;34:975-87.
30. Bolard J, Joly V, Yeni Y. Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery systems. J Liposomal Res 1993;3:409-27.
31. Chia JKS, Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis 1989;159:113-6.
32. Yamaguchi H, Abe S, Tokuda Y. Immunomodulating activity of antifungal drugs. Ann N Y Acad Sci 1993;685:447-57.
33. Juliano RL, Grant CWM, Barber KR, Kalp MA. Mechanism of selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987;31:1-11.
34. Clemons KV, Stevens DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991;35:2144-6.
35. Lee J, Allende M, Amantea M, Francis P, Peter J, Thomas V, et al. Pharmacokinetics and efficacy of amphotericin B lipid complex (Abelcet) against chronic disseminated candidiasis in rabbits (abstract). In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 29-October 2, 1991:195.
36. Lee J, Allende M, Dollenberg H, Garrett K, Berenguer J, Francesconi A, et al. Reticuloendothelial loading with amphotericin B lipid complex (Abelcet) - a novel pharmacodynamic approach to treatment of experimental hepatosplenic candidiasis (HSC) (abstract). In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11-14, 1992:139.
37. Allendoerfer R, Yates RR, Sun SH, Graybill JR. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1991;30:377-84.
38. Clemons KV, Stevens DA. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother 1992;30:353-63.
39. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35: 615-21.
40. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13:271-6.
41. Christensen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985;152:1037-43.
42. Collette N, van der Auwera P, Pascual Lopez A, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989;33:362-8.
43. Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis 1992;15: 654-7.
44. Kan V, Bennett J, Amantea M, Smolskis M, McManus D, Grasela D, et al. Comparative safety and pharmacokinetic study of amphotericin B lipid complex and amphotericin B deoxycholate in healthy young male volunteers. J Infect Dis 1991;164:418-25.
45. Grasela D, Echevarria J, Summerill R, Gonzalez D, Christafalo B, Chang J, et al. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex (Abelcet) or Fungizone (FZ) in adults with mucocutaneous leishmaniasis (abstract). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17-20, 1993:382.
46. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
47. Anaissie EJ, White M, Uzun O, Singer C, Bodey GP, Matzke D, et al. Amphotericin B lipid complex (Abelcet) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective randomized multicenter trial (abstract). In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, CA, September 17-20, 1995:330.
48. Hiemenz JW, Lister J, Anaissie EJ, White MH, Dinubile M, Silber J, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B (abstract). Blood 1995;86(suppl 1):849a.
49. Lister J. Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy (abstract). Blood 1994;84(suppl):306a.
50. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis (abstract). In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4-7, 1994:247.
51. Sharkey PK, Lipke R, Renteria A, Gulgini J, Catanzano A, Diaz M, et al. Amphotericin B lipid complex (ABLC) in the treatment (Rx) of coccidioidomycosis (abstract). In: Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 29-October 2, 1991:222.
52. Anaissie EJ, Rubin R. Efficacy and safety of amphotericin B lipid complex (ABLC) in the treatment of patients with life-threatening fusariosis (abstract). In: Programs and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 2-4, 1994:248.
53. Lister J. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996; 56(suppl):18-23.
54. Powderly WG. Editorial response: management of cryptococcal meningitis - have we answered all the questions? Clin Infect Dis 1996;22: 329-30.
55. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey P, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992; 326:83-9.
56. van der Horst C, Saag M, Cloud GA, Hamill R, Graybill R, Sobel J, et al. Randomized double blind comparison of amphotericin B plus flucytosine to AmB alone (STEP 1) followed by a comparison of fluconazole to itraconazole (STEP 2) in the treatment of acute cryptococcal meningitis in patients with AIDS: part 1 (abstract). In: Proceedings and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995:244.
57. Saag M, van der Horst C, Cloud GA, Hamill R, Graybill R, Sobel J, et al. Randomized double blind comparison of amphotericin B plus flueytosine to AmB alone (STEP 1) followed by a comparison of fluconazole to itraconazole (STEP 2) in the treatment of acute cryptococcal meningitis in patients with AIDS: part 2 (abstract). In: Proceedings and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995:244.
58. Jones RS, Barman A, Suh B, Heifets M, Bocobo FC. Successful treatment of aspergillus vertebral osteomyelitis with amphotericin B lipid complex. Infect Dis Clin Pract 1995;4:237-9.
59. Hospenthal DR, Byrd JC, Weiss RB. Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. Med Ped Oncol 1995;25:119-22.
60. Wingard JR, Walker RC. Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses (abstract). Blood 1994;84(suppl):486a.
61. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B complex. J Infect Dis 1996:173:762-5.
62. Naguib MT, Huycke MM, Pederson JA, Pennington LR, Burton ME, Greenfield RA. Apophysomyces elegans infection in a renal transplant recipient. Am J Kidney Dis 1995;26:381-4.
63. Wolff MA, Ramphal R. Use of amphotericin B lipid complex for treatment of disseminated cutaneous fusarium infection in a neutropenic patient (letter). Clin Infect Dis 1995;20:1568.
64. Package insert. Abelcet (amphotericin B lipid complex). Princeton, NJ: The Liposome Company, December 1996.
65. Kline S, Larsen T, Fieber L, Fishbach R, Greenwood M, Harris R, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:1154-8.
66. Cleary JD, Weisdorf D, Fletcher CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm 1988;22: 769-72.
67. Purchasing records. Lexington, KY: Department of Pharmacy, University of Kentucky Hospital (University Hospital Consortium Pricing). June 1997.